Fiche société
Northside Hospital, Inc.
Traitements, essais et publications liés.
Traitements1programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
1| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| graft-versus-tumor induction therapyRATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and to see how well it works in treating patients with high-risk hematologic cancer. | SEP | Phase 2 | Thérapie cellulaire | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Alemtuzumab | SEP | Phase 2 | NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | TERMINATED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||